PRVA

Over the past six months, Privia Health Group, Inc. reported strong Q1 2026 earnings on May 7, 2026, with revenue up 25.8% and adjusted EBITDA up 36.3% year-over-year, reiterating full-year guidance. On May 27, 2026, the company announced its expansion into New Jersey, increasing its presence to 25 states. Strong Q2 2026 earnings were reported on August 6, 2026, with revenue of $632.6 million (up 21.4%), net income attributable to Privia rising to $9.0 million (a 236.7% increase), and adjusted EBITDA growing 29.1% to $37.4 million, leading to raised full-year 2026 guidance. On August 18, 2026, Opella Ernest, M.D. was appointed to its Board of Directors, effective September 1, 2026. The company is scheduled to release its Q3 2026 earnings report on November 5, 2026. As of October 8, 2026, PRVA closed at $20.19, having lost 17.7% over the past 12 months, but shares rose 3.3% to $20.85 on October 9, 2026. The stock has traded between a 52-week high of $28.82 and a low of $18.92.